ConductScience.org, home

Paper2860883

Antihypertensive therapy and lipids. Evidence, mechanisms, and implications.

Weinberger MH. Arch Intern Med, 1985. Cited by 201 papers, by iCite.

Cite this record

ConductScience Library. Antihypertensive therapy and lipids. Evidence, mechanisms, and implications. Papers, record 2860883. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2860883

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Antihypertensive therapy and lipids. Evidence, mechanisms, and implications.
PubMed
Journal
Arch Intern Med
PubMed
Year
1985
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
201
iCite
Relative citation ratio, by iCite
10.2
iCite
Revised in PubMed
2013-11-21
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Weinberger MHM H

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antihypertensive AgentsMajor topic
Coronary DiseaseMajor topic
Dietary FatsMajor topic
HypertensionMajor topic
Lipid MetabolismMajor topic
Adrenergic beta-Antagonists
Cholesterol
Diuretics
Humans
Lipoproteins
Longitudinal Studies
Male
Risk
Sympatholytics
Triglycerides
Vasodilator Agents

Source PubMed

Download CSV of topics

Cited by26

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 201 citations.

PMIDTitleJournalYearIn PapersSource
39861195Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy-Challenges and Prospectives.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/39861195PubMed
36945026The impact of rate and rhythm control strategies on quality of life for patients with atrial fibrillation: a protocol for a systematic review.Syst Rev2023https://conductscience.org/library/papers/36945026PubMed
8527351
Comparison of the efficacy and safety of once-daily versus twice-daily formulations of diltiazem in the treatment of systemic hypertension. The Canadian Multicenter Diltiazem-CD Hypertension Trial Group.
Cardiovasc Drugs Ther1995https://conductscience.org/library/papers/8527351PubMed
8133348Primary care of the renal transplant patient.J Gen Intern Med1994https://conductscience.org/library/papers/8133348PubMed
7875191Lack of interaction between ramipril and simvastatin.Eur J Clin Pharmacol1994https://conductscience.org/library/papers/7875191PubMed
7556989A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.Diabetologia1995https://conductscience.org/library/papers/7556989PubMed
3765601Antihypertensive therapy, serum lipids, coronary heart disease and hypertension--balancing the risks and benefits of treatment.West J Med1986https://conductscience.org/library/papers/3765601PubMed
3595696Serum lipids and lipoproteins in ischaemic heart disease following withdrawal of long-term metoprolol treatment.Eur J Clin Pharmacol1987https://conductscience.org/library/papers/3595696PubMed
3545419Billing numbers fight to continue despite court setback.CMAJ1987https://conductscience.org/library/papers/3545419PubMed
3319640Comparison of nicardipine and propranolol in the treatment of mild and moderate hypertension.Eur J Clin Pharmacol1987https://conductscience.org/library/papers/3319640PubMed
3190999Quinapril and blood lipids.Br J Clin Pharmacol1988https://conductscience.org/library/papers/3190999PubMed
3154682Comparison of the metabolic effects of long-term treatment with pindolol or atenolol by hypertensive patients.Cardiovasc Drugs Ther1988https://conductscience.org/library/papers/3154682PubMed
3154313Angiotensin converting enzyme inhibitors in the treatment of hypertension: efficacy, metabolic effects and side effects.Cardiovasc Drugs Ther1987https://conductscience.org/library/papers/3154313PubMed
3077110Value of non-drug treatment and drug treatment in hypertension.Drugs1988https://conductscience.org/library/papers/3077110PubMed
2939868A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension.Br J Clin Pharmacol1986https://conductscience.org/library/papers/2939868PubMed
2846658Mechanisms underlying transition from acute glomerular injury to late glomerular sclerosis in a rat model of nephrotic syndrome.J Clin Invest1988https://conductscience.org/library/papers/2846658PubMed
2655692Low and conventional dose cyclopenthiazide on glucose and lipid metabolism in mild hypertension.Br J Clin Pharmacol1989https://conductscience.org/library/papers/2655692PubMed
2565758Recommendations from the Canadian Hypertension Society Consensus Conference on the Pharmacologic Treatment of Hypertension.CMAJ1989https://conductscience.org/library/papers/2565758PubMed
2518682Cost of antihypertensive treatment: a point of view from India.Cardiovasc Drugs Ther1989https://conductscience.org/library/papers/2518682PubMed
2488113Effects of pindolol and propranolol on blood lipids in hypertensive patients.Cardiovasc Drugs Ther1989https://conductscience.org/library/papers/2488113PubMed

See all 26 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2860883

GET https://conductscience.org/api/papers/v1/2860883/cited_by?page=2